British Journal of Cancer

FIGURE 1

FROM:

A phase 1 study of tazarotene in adults with advanced cancer

P H Jones, R D Burnett, I Fainaru, P Nadolny, P Walker, Z Yu, D Tang-Liu, T S Ganesan, D C Talbot, A L Harris and G J S Rustin

BACK TO ARTICLE

Figure 1.

Figure and tables index
Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

(A) Plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. (B) Plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. (C) Dose-normalised (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. (D) Dose-normalised (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. (E) Dose-normalised (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients at week 4. (F) Dose-normalized (1 mg) plasma concentrations (meanplusminuss.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in five cancer patients at week 4.

Figure and tables index
BACK TO ARTICLE